In the base-case scenario (5-year time horizon), the average costs were SFED: $15,296.81, PPI: $16,153.77, and tCS: $20,975.33 as initial therapy, with SFED being the dominant strategy (more effective/less costly), while PPI offered the lowest cost on a 2-year time horizon. From a societal perspective, PPI was the dominant initial strategy on both 2 and 5-year time horizons. Among pharmacologic therapies, PPI was the most cost-effective first-line option. Dupilumab was not cost-effective relative to tCS, unless the quarterly cost is reduced from $7,311 to $2,038.50 per price threshold analysis under permissive modeling conditions., Find the most popular and affordable Eosinophilic Esophagitis medication. Save with or without insurance on brand and generic alternatives used to treat Eosinophilic Esophagitis., Compare risks and benefits of common medications used for Eosinophilic Esophagitis. Find the most popular drugs, view ratings and user reviews..